Evidence map›Paper›PMID 29344295›Full record

ArticleTheranostics2018

Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients.

Constantin Lapa, Malte Kircher, Heribert Hänscheid, Andreas Schirbel, Götz Ulrich Grigoleit, Erdwine Klinker, Markus Böck, Samuel Samnick, Theo Pelzer, Andreas K Buck

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Biodistribution and first clinical results ofEuropean journal of nuclear medicine and molecular imaging · 2020
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Constantin LapaDepartment of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Malte KircherDepartment of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Heribert HänscheidDepartment of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Andreas SchirbelDepartment of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Götz Ulrich GrigoleitDepartment of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
Erdwine KlinkerInstitute for Transfusion Medicine and Hemotherapy, University Hospital Würzburg, Würzburg, Germany.
Markus BöckInstitute for Transfusion Medicine and Hemotherapy, University Hospital Würzburg, Würzburg, Germany.
Samuel SamnickDepartment of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Theo PelzerCenter for Rare Diseases - Reference Center Northern Bavaria (ZESE), Würzburg, Germany.
Andreas K BuckDepartment of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Universitätsklinikum Würzburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sarcoidosis is a multisystem granulomatous disorder of unknown etiology that can involve virtually all organ systems. Whereas most patients present without symptoms, progressive and disabling organ failure can occur in up to 10% of subjects. Somatostatin receptor (SSTR)-directed peptide receptor radionuclide therapy (PRRT) has recently received market authorization for treatment of SSTR-positive neuroendocrine tumors.

Indexed as

FemaleHumansMiddle AgedOctreotideRadiopharmaceuticalsSarcoidosis177Lu-octreotide, DOTA(0)-Tyr(3)-OctreotideRadiopharmaceuticalspeptide receptor radionuclide therapyPRRTSarcoidosissomatostatin receptors

Identifiers

PMID29344295
PMCPMC5771082
OpenAlexW2770455617

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.